Key Points
- Berndt Modig sold 23,333 shares of Pharvaris on April 9 at an average price of $27.74 under a pre-arranged Rule 10b5-1 plan, generating about $647,257 and reducing his holding by 14.11% to 142,084 shares (~$3.94M).
- Analyst and market backdrop: PHVS trades near $26.63 with a $1.74B market cap and a 52‑week range of $11.66–$29.85, and carries a consensus "Moderate Buy" from analysts (11 Buys) with an average target of $42.73.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 23,333 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total value of $647,257.42. Following the completion of the transaction, the chief executive officer owned 142,084 shares of the company's stock, valued at $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pharvaris Stock Performance
Shares of PHVS opened at $26.63 on Friday. Pharvaris N.V. has a 52 week low of $11.66 and a 52 week high of $29.85. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.90 and a beta of -2.58. The stock has a fifty day moving average of $27.05 and a 200-day moving average of $25.52.
Analyst Upgrades and Downgrades
PHVS has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research note on Thursday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a research note on Sunday, April 5th. Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a report on Monday, April 6th. Finally, Wedbush increased their price objective on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $42.73.
Read Our Latest Report on Pharvaris
Institutional Trading of Pharvaris
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System increased its holdings in Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company's stock valued at $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the period. HighVista Strategies LLC increased its holdings in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company's stock valued at $418,000 after purchasing an additional 971 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Pharvaris in the fourth quarter valued at $35,000. Finally, Public Employees Retirement System of Ohio increased its holdings in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company's stock valued at $210,000 after purchasing an additional 1,300 shares during the period.
Pharvaris News Roundup
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Wolfe Research initiated coverage with an "Outperform" rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
- Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris' growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
- Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
- Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
- Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
